Ross C Donehower
Professor
Oncology
Johns Hopkins University
United States of America
Biography
Director, Medical Oncology/Hematogy Fellowship Training Program Director, Division of Medical Oncology Virginia and D.K. Ludwig Professor in Clinical Investigation of Cancer Professor of Oncology Professor of Medicine
Research Interest
Gastrointestinal Cancers ; New Anticancer Drug Development ; Pharmacology
Publications
-
Sommer, M.; Poliak, N.; Upadhyay, S.; Ratovitski, E.; Nelkin, B.D.; Donehower, L.A.; Sidransky, D. DeltaNp63alpha overexpression induces downregulation of Sirt1 and an accelerated aging phenotype in the mouse. Cell Cycle. 2006 Sep;5(17):2005-2011.
-
Messersmith, W.A.; Baker, S.D.; Lassiter, L.; Sullivan, R.A.; Dinh, K.; Almuete, V.I.; Wright, J.J.; Donehower, R.C.; Carducci, M.A.; Armstrong, D.K. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2006 Feb 15;12(4):1270-1275.
-
Gilbert, J.; Carducci, M.A.; Baker, S.D.; Dees, E.C.; Donehower, R. A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies. Invest New Drugs. 2006 Nov;24(6):499-508.
